Earnings

Janux Therapeutics Q3 EPS $(0.34) Beats $(0.46) Estimate, Sales $9.290M Beat $7.746M Estimate

Nov 5, 2026 · 04:26 PM ET· updated 1h ago

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 12.82 percent increase over losses of $(0.39) per share

Why It Matters

Janux lost less money than people expected this quarter. When a company does better than predicted, it often means things are improving.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

JANX16.04

-2.14 (-11.77%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.